Kennedy Capital Management LLC Has $2.46 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Kennedy Capital Management LLC lifted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 2.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 193,912 shares of the company’s stock after purchasing an additional 4,615 shares during the quarter. Kennedy Capital Management LLC owned 0.19% of Day One Biopharmaceuticals worth $2,457,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of DAWN. FMR LLC grew its position in Day One Biopharmaceuticals by 73.9% during the 4th quarter. FMR LLC now owns 12,887,467 shares of the company’s stock worth $163,284,000 after purchasing an additional 5,475,087 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Day One Biopharmaceuticals by 17.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company’s stock worth $44,219,000 after buying an additional 507,398 shares during the period. Wellington Management Group LLP grew its holdings in shares of Day One Biopharmaceuticals by 142.1% during the third quarter. Wellington Management Group LLP now owns 721,581 shares of the company’s stock valued at $10,052,000 after buying an additional 423,543 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in Day One Biopharmaceuticals during the fourth quarter valued at $2,726,000. Finally, Norges Bank purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth about $2,141,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Up 5.3 %

Shares of DAWN opened at $7.12 on Monday. The firm has a market cap of $721.65 million, a price-to-earnings ratio of -6.91 and a beta of -1.24. The company’s fifty day moving average is $9.33 and its 200-day moving average is $12.03. Day One Biopharmaceuticals, Inc. has a 12 month low of $6.41 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million. As a group, research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DAWN. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Wedbush reiterated an “outperform” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Finally, Bank of America cut their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.29.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.